Osteoporosis drugs have a reputation problem. Most people picture them as bone-preserving at best — slowing breakdown, not adding new tissue. That impression is accurate for bisphosphonates, which is exactly why a second FDA-approved anabolic peptide often surprises people. If your doctor mentioned abaloparatide, your first questions are probably: Is this just another version of

Salmon calcitonin has been around long enough that most physicians learned about it before newer bone drugs existed. It was FDA-approved decades ago, once used widely for osteoporosis, and still carries approved indications today. But it also carries something else: a 2014 regulatory narrowing driven by a cancer risk signal and, separately, a long-running question